Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis

References

• Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol.4, 435–459 (2009).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, Definitions, epidemiology, pathophysiology, diagnosis, and staging. Am. J. Respir. Crit. Care Med.152, S78–S83 (1995).
   Web of Science ®Google Scholar
• Miravitlles M. Do we need new antibiotics for treating exacerbations of COPD? Ther. Adv. Respir. Dis.1, 61–76 (2007).
   PubMedGoogle Scholar
• Meyer KC. Aging. Proc. Am. Thorac. Soc.2, 433–439 (2005).
   PubMedGoogle Scholar
• Hayes D Jr, Meyer KC. Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management. Drugs Aging24, 555–572 (2007).
   PubMed Web of Science ®Google Scholar
• Brunton S, Carmichael BP, Colgan R et al. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am. J. Manag. Care10, 689–696 (2004).
   PubMed Web of Science ®Google Scholar
• Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J.10(Suppl. B), 3B–32B (2003).
   PubMedGoogle Scholar
• Burgel PR, Nesme-Meyer P, Chanez P et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest135, 975–982 (2009).
   PubMed Web of Science ®Google Scholar
• Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest123, 1684–1692 (2003).
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther.21, 576–591 (1999).
   PubMed Web of Science ®Google Scholar
• Niederman MS, Anzueto A, Sethi S et al. Eradication of H. influenzae in AECB: a pooled analysis of moxifloxacin Phase III trials compared with macrolide agents. Respir. Med.100, 1781–1790 (2006).
   PubMed Web of Science ®Google Scholar
• Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest117, 1S–4S (2000).
   Google Scholar
• Connolly MJ, Lowe D, Anstey K, Hosker HS, Pearson MG, Roberts CM, Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organisation. Thorax61, 843–848 (2006).
   PubMed Web of Science ®Google Scholar
• Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax57, 137–141 (2002).
   PubMed Web of Science ®Google Scholar
• McGuire A, Irwin DE, Fenn P et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health4, 370–375 (2001).
   PubMedGoogle Scholar
• Rennie RP, Ibrahim KH. Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin. Infect. Dis.41(Suppl. 4), S234–S238 (2005).
   Google Scholar
• O’Donnell AE. Bronchiectasis. Chest134, 815–823 (2008).
   PubMed Web of Science ®Google Scholar
• Neralla S, Meyer KC. Drug treatment of pneumococcal pneumonia in the elderly. Drugs Aging21, 851–864 (2004).
   PubMed Web of Science ®Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill. Summ.51, 1–16 (2002).
   PubMed Web of Science ®Google Scholar
• Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest117, 380S–385S (2000).
   Google Scholar
• Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med.106, 196–204 (1987).
   PubMed Web of Science ®Google Scholar
• Patel IS, Vlahos I, Wilkinson TM et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.170, 400–407 (2004).
   PubMed Web of Science ®Google Scholar
• Blasi F, Ewig S, Torres A, Huchon G. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm. Pharmacol. Ther.19, 361–369 (2006).
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Grossman RF, Zadeikis N et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur. Respir. J.25, 1001–1010 (2005).
   PubMed Web of Science ®Google Scholar
• Poole P, Chacko EE, Wood-Baker R, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease (Review). Cochrane Database Syst. Rev.1, CD002733 (2006).
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Hernandez P, Kaplan A et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can. Respir. J.15(Suppl. A), 1A–8A (2008).
   PubMed Web of Science ®Google Scholar
• Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp. Gerontol.38, 843–853 (2003).
   PubMed Web of Science ®Google Scholar
• Sin D, Tu J. Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonary disease. Can. Respir. J.7(6), 466–471 (2000).
   PubMedGoogle Scholar
• El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax63, 415–422 (2008).
   PubMed Web of Science ®Google Scholar
• Milstone AP. Use of azithromycin in the treatment of acute exacerbations of COPD. Int. J. Chron. Obstruct. Pulmon. Dis.3, 515–520 (2008).
   PubMedGoogle Scholar
• Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos II. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J. Antimicrob. Chemother.62, 442–450 (2008).
   PubMed Web of Science ®Google Scholar
• Pea F, Pavan F, Lugatti E et al. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Clin. Pharmacokinet.45, 287–295 (2006).
   PubMed Web of Science ®Google Scholar
• Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr. Opin. Pulm. Med.14, 595–599 (2008).
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med.178, 1139–1147 (2008).
   PubMed Web of Science ®Google Scholar
• Sullivan JT, Lettieri JT, Liu P, Heller AH. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin. Pharmacokinet.40(Suppl. 1), 11–8 (2001).
   PubMed Web of Science ®Google Scholar
• Ball P, Mandell L, Patou G, Dankner W, Tillotson G. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int. J. Antimicrob. Agents23, 421–429 (2004).
   PubMed Web of Science ®Google Scholar
• Anzueto A, Gotfried M, Wikler MA, Russo R, Nicholson SC. Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis. Clin. Ther.24, 916–917 (2002).
   Google Scholar
• Dimopoulos G, Siempos II, Korbila IP, Manta KG, Falagas ME. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest132, 447–455 (2007).
   PubMed Web of Science ®Google Scholar
• Siempos II, Dimopoulos G, Korbila IP, Manta K, Falagas ME. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J.29, 1127–1137 (2007).
   PubMed Web of Science ®Google Scholar
• Grossman RF, Ambrusz ME, Fisher AC, Khashab MM, Kahn JB. Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. Clin. Ther.28, 1175–1180 (2006).
   PubMed Web of Science ®Google Scholar
• Petitpretz P, Chone C, Tremolieres F. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int. J. Antimicrob. Agents30, 52–59 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson R, Langan C, Ball P, Bateman K, Pypstra R. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir. Med.97, 242–249 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest125, 953–964 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson R, Jones P, Schaberg T, Arvis P, Duprat-Lomon I, Sagnier PP. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax61, 337–342 (2006).
   PubMed Web of Science ®Google Scholar
• Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int. J. Antimicrob. Agents29, 56–61 (2007).
   PubMed Web of Science ®Google Scholar
• Grassi C, Casali L, Curti E, Tellarini M, Lazzaro C, Schito G. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J. Chemother.14, 597–608 (2002).
   PubMed Web of Science ®Google Scholar
• Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents23, 129–137 (2004).
   PubMed Web of Science ®Google Scholar
• Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J. Int. Med. Res.29, 314–328 (2001).
   PubMed Web of Science ®Google Scholar
• Urueta-Robledo J, Ariza H, Jardim JR et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir. Med.100, 1504–1511 (2006).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ros F, Cobos A, Kubin R, Tillotson G. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience. Int. J. Clin. Pract.55, 437–441 (2001).
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Llor C, Naberan K, Cots JM, Molina J. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir. Med.99, 955–965 (2005).
   PubMed Web of Science ®Google Scholar
• Schaberg T, Moller M, File T, Stauch K, Landen H. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice. Clin. Drug Investig.26, 733–744 (2006).
   PubMed Web of Science ®Google Scholar
• Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis.41, 118–121 (2005).
   PubMed Web of Science ®Google Scholar
• Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis.6, 629–640 (2006).
   PubMed Web of Science ®Google Scholar
• Amsden GW, Baird IM, Simon S, Treadway G. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest123, 772–777 (2003).
   PubMed Web of Science ®Google Scholar